Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > shareholder interaction 101, note taking, not a doormat

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Jan 06, 2024 2:34pm

123 Views

Post# 35813921

RE:RE:RE:RE:RE:RE:shareholder interaction 101, note taking, not a doormat

There's you claiming to have info that you don't! If I only I knew what?

Canadafan has yet to pretend he's had convoluted conversations with members of the board, who've divulged opinion and company business randomly.

You've just regurgitated the same stuff that is posted every day. Everyone knows the current state of play, you don't need to go on and on and on........ When you have new info please let us know.

<< Previous

Bullboard Posts

Next >>

The long-term forecast for lithium stocks in 2024